Nonsteroidal anti-inflammatory drugs (NSAIDs) might still have a role in treating axial spondylarthritis, but other drugs, therapies are being explored
When Will Generic Biologic Drugs Become Commercially Available?
Biosimilars are challenging to produce, but progress is being made
Tofacitinib and Other Kinase Inhibitors Offer New Approach to Treating Rheumatoid Arthritis
Small molecule kinase inhibitors, such as JAK inhibitors, provide a novel route for rheumatic disease treatment—and may promote our understanding of the immune system’s complexities
Rheumatology Drug Updates: Apremilast, Golimumab, and More
Information on new approvals and medication safety rheumatologists need to know
Drug Updates: Lorcaserin, Acetaminophen, and More
information on new approvals and medication safety
EULAR 2012: Remission the New Normal for Rheumatoid Arthritis
Advances in the rheumatology clinic are promising, two experts say.
American College of Rheumatology Leads Charge to Address Excessive Patient Cost Sharing
The ACR Government Affairs Committee has developed legislative language to limit commercial insurance plans’ cost-sharing requirements for medications in a specialty drug tier to the dollar amount applicable to drugs in the nonpreferred-brand drug tier.
Managing an In-Office Infusion Practice
The increased utilization of infusible biologics for the treatment of rheumatic diseases has opened the door for you to provide more integrated care for your patients. Having an in-office infusion center gives you the ability to deliver this service to your patients in a familiar and supportive setting.
Drug Updates: EULAR 2012
Tracking the results of drug safety and efficacy
Drug Updates
Information on new approvals and medication safety.